PolymarketChiusoVerifica disponibilitàSenza KYC2% di commissioneDati di risoluzione verificatiDiscretamente calibratoQuesto mercato si è risolto: No
Risolto: 11 giu 2026, 09:52
Risoluzione verificata dal provider
CoinRithm dispone di prove del provider sul vincitore e sul momento di regolamento di questo mercato.
Esito Vincente
No
A 7 giorni
—
A 24 ore
8%
SorpresaProbabilità implicita attuale
No 100%+0.9pt
Qualita del mercato
22 / 100
Bassa qualitàVolume 24h
799,3 €
Liquidità
—
Liquidità sconosciutaBid / Ask
- / 0.4%
Dati di mercato
Aggiornato 70 giorni fa
Obsoleto4 giu 26, 19:3510 giu 26, 0:00
Cronologia delle Probabilità
Yes0%
No100%
100%
0%
Regole
As of market creation, the FDA's expected decision date for the specified application is June 10, 2026.
- This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for Camurus's Oclaiz as a treatment for patients with acromegaly by June 24, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
